BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 34781735)

  • 1. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
    Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
    mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.
    Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells.
    Xu JX; Zhang R; Huang DJ; Tang Y; Ping LQ; Huang BJ; Huang HQ; Busson P; Li J
    Microbiol Spectr; 2023 Feb; 11(1):e0493222. PubMed ID: 36622166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Evasion by Epstein-Barr Virus.
    Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
    Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.
    Abbott RJ; Pachnio A; Pedroza-Pacheco I; Leese AM; Begum J; Long HM; Croom-Carter D; Stacey A; Moss PAH; Hislop AD; Borrow P; Rickinson AB; Bell AI
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
    Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
    J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
    Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
    J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
    J Virol; 2020 May; 94(10):. PubMed ID: 32132242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.
    Williams LR; Quinn LL; Rowe M; Zuo J
    J Virol; 2016 Jan; 90(2):947-58. PubMed ID: 26537677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential cellular functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus.
    Westhoff Smith D; Sugden B
    Viruses; 2013 Jan; 5(1):226-40. PubMed ID: 23325328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
    Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
    Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
    Hochberg D; Middeldorp JM; Catalina M; Sullivan JL; Luzuriaga K; Thorley-Lawson DA
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):239-44. PubMed ID: 14688409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.
    Campion EM; Hakimjavadi R; Loughran ST; Phelan S; Smith SM; D'Souza BN; Tierney RJ; Bell AI; Cahill PA; Walls D
    J Virol; 2014 May; 88(9):5001-13. PubMed ID: 24554662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic profiling of EBNA1-host protein interactions in latent and lytic Epstein-Barr virus infections.
    Malik-Soni N; Frappier L
    J Virol; 2012 Jun; 86(12):6999-7002. PubMed ID: 22496234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
    Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
    Liu CD; Lee HL; Peng CW
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
    Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
    Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.